Glucocerebrosidase (GBA) and leucine-rich repeat kinase 2 (LRRK2) mutation carriers have a higher age-specific risk of PD diagnosis compared with non-carriers (both estimated to be about 30% at the age of 80 years) [29–31] . The gene discussed is LRRK2; the disease is Parkinson disease.